IRulya Therapeutics Inc. Common Stock
IRLA
32 hedge funds and large institutions have $4.04M invested in IRulya Therapeutics Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 11 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
2.46% less ownership
Funds ownership: 14.46% → 12% (-2.5%)
14% less capital invested
Capital invested by funds: $4.68M → $4.04M (-$640K)
22% less funds holding
Funds holding: 41 → 32 (-9)
82% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Almitas Capital
Santa Monica,
California
|
+$274K |
| 2 |
SC
Shay Capital
New York
|
+$123K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$47.4K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$35.8K |
| 5 |
Mariner
Overland Park,
Kansas
|
+$34.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.13M |
| 2 |
Two Sigma Advisers
New York
|
-$70.2K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$47.3K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$35.8K |
| 5 |
Millennium Management
New York
|
-$27.4K |
IRLA Hedge Fund Activity: Q3 2024 in Review
32 of the 6,982 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q3 2024, worth a combined $4.04M — down 14% from $4.68M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of IRLA and 2 opened new positions — a net loss of 9 holders — while 5 trimmed existing stakes and 10 added.
The largest buyer was Almitas Capital, opening a new position worth an estimated $274K. The largest seller was Tang Capital Management, exiting entirely with an estimated $1.13M sold.
- 32 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q3 2024, down from 41 in Q2 2024.
- Funds reported $4.04M of IRulya Therapeutics Inc. Common Stock stock for Q3 2024, down 14% quarter-over-quarter.
- 2 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q3 2024 and 11 closed out, a net change of -9 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q3 2024 was Almitas Capital, an estimated $274K added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q3 2024 was Tang Capital Management, an estimated $1.13M sold.
Based on aggregated 13F filings for Q3 2024.